Regeneron Gives Statement on Stock Halt, Cites FDA Meeting For Praluent Today

Regeneron Pharmaceuticals, Inc. REGN today announced that NASDAQ has halted trading of the company's common stock. The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is meeting today to discuss the company's Biologics License Application (BLA) for Praluent® (alirocumab) Injection.